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Introduction: Transplantation of bone marrow mesenchymal stem cells (BMSCs) can repair injured hearts. However,
whether BMSC populations contain cells with cardiac stem cell characteristics is ill-defined. We report here that
Notch signalling can promote differentiation of c-KitPOS/NKX2.5POS BMSCs into cardiomyocyte-like cells.
Methods: Total BMSCs were isolated from Sprague–Dawley rat femurs and c-KitPOS cells were purified. c-KitPOS/NKX2.5POS
cells were isolated by single-cell cloning, and the presence of cardiomyocyte, smooth muscle cell (SMC), and endothelial
cell differentiation markers assessed by immunofluorescence staining and semi-quantitative reverse-transcription
polymerase chain reaction (RT-PCR) analysis. Levels of c-Kit and Notch1–4 in total BMSCs and c-KitPOS/NKX2.5POS
BMSCs were quantitated by flow cytometry. Following infection with an adenovirus over-expressing Notch1
intracellular domain (NICD), total BMSCs and c-KitPOS/NKX2.5POS cells were assessed for differentiation to cardiomyocyte,
SMC, and endothelial cell lineages by immunofluorescence staining and real-time quantitative RT-PCR. Total BMSCs and
c-KitPOS/NKX2.5POS cells were treated with the Notch1 ligand Jagged1 and markers of cardiomyocyte, SMC, and
endothelial cell differentiation were examined by immunofluorescence staining and real-time quantitative RT-PCR
analysis.
Results: c-KitPOS/NKX2.5POS cells were present among total BMSC populations, and these cells did not express
markers of adult cardiomyocyte, SMC, or endothelial cell lineages. c-KitPOS/NKX2.5POS BMSCs exhibited a multi-lineage
differentiation potential similar to total BMSCs. Following sorting, the c-Kit level in c-KitPOS/NKX2.5POS BMSCs was 84.4%.
Flow cytometry revealed that Notch1 was the predominant Notch receptor present in total BMSCs and c-KitPOS/NKX2.5POS
BMSCs. Total BMSCs and c-KitPOS/NKX2.5POS BMSCs overexpressing NICD had active Notch1 signalling accompanied by
differentiation into cardiomyocyte, SMC, and endothelial cell lineages. Treatment of total BMSCs and c-KitPOS/NKX2.5POS
BMSCs with exogenous Jagged1 activated Notch1 signalling and drove multi-lineage differentiation, with a
tendency towards cardiac lineage differentiation in c-KitPOS/NKX2.5POS BMSCs.
Conclusions: c-KitPOS/NKX2.5POS cells exist in total BMSC pools. Activation of Notch1 signalling contributed to
multi-lineage differentiation of c-KitPOS/NKX2.5POS BMSCs, favouring differentiation into cardiomyocytes. These
findings suggest that modulation of Notch1 signalling may have potential utility in stem cell translational medicine.* Correspondence: szh75@126.com; Jiewei74@126.com
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Stem cell transplantation is emerging as a promising
method to repair heart injuries [1-3]. Stem cells are self-
replicating multipotent cells that can differentiate into a
variety of cell types under certain conditions. Various
types of stem cells, including bone marrow cells (BMCs),
mesenchymal stem cells, haematopoietic stem cells, and
adipose-derived stem cells, have been used in cellular
therapies to repair damage following myocardial infarc-
tion (MI). Phase I and II clinical trials have shown that
transplantation of adult BMCs in patients with ischaemic
heart disease improves left ventricle function and infarct
size even at long-term follow-up, compared with stand-
ard therapy [4]. However, several recent clinical trials
(SWISS-AMI, CELLWAVE, and C-CURE) for MI ther-
apy involving BMCs have produced conflicting results
[5-7], leading to debate concerning the efficacy of BMCs
in treating heart disease [8].
The discovery of endogenous stem cells within heart
tissue, termed cardiac stem cells (CSCs), offers great
potential for stem cell research [9]. CSCs have self-
renewal and differentiation capacities that are necessary
and sufficient for MI repair [10]. The phase I clinical
trials SCIPIO (ClinicalTrials.gov NCT00474461) and
CADUCEUS (ClinicalTrials.gov NCT00893360) have
been conducted using autologous CSCs [11,12]. The
feasibility, safety, and effectiveness of autologous CSC
injection were assessed in these trials, with encouraging
preliminary results evidenced by a reduction in the
myocardial scar mass or improvement in the left ven-
tricular ejection fraction following cell treatment. How-
ever, a major obstacle limiting the clinical application
of endogenous CSCs is the requirement for heart tis-
sues as a cellular source, which increases the risk of in-
jury and complications. Furthermore, obtaining the
desired cell numbers for in vivo transplantation is time
consuming because heart tissue-derived CSCs grow
slowly. There is therefore a need for an alternative and
easily accessible cell source that can be substituted for
endogenous CSCs.
Mesenchymal stem cells are multipotent stem cells
that can be easily obtained and handled, and which ex-
hibit multilineage differentiation potential [13]. As ideal
seed cells, mesenchymal stem cells have been widely
used in tissue engineering, cell transplantation, and gene
therapy. Mesenchymal stem cell transplantation contrib-
utes to the recovery of heart injuries, including those
caused by MI, mainly through angiogenesis, paracrine
signalling, activation of endogenous CSCs, and anti-
inflammatory effects – but not differentiation [14]. In
the C-CURE trial, bone marrow mesenchymal stem cells
(BMSCs) were exposed to a cocktail of cardiogenic
growth factors prior to cell transplantation, which pro-
moted in vivo functions post transplantation [6]. Thiseffect demonstrates that activating certain signalling
pathways in stem cells can promote desirable biofunc-
tions in vivo. The heterogeneity of BMSCs may account
for their low efficiency of cardiomyocyte differentiation
in vivo, thus limiting their long-term potential to repair
heart injuries. The isolation of a specific subpopulation
of MSCs with a tendency for cardiomyocyte differenti-
ation under the influence of specific signalling would
therefore be of great value to stem cell translational
medicine.
The Notch signalling pathway is highly conserved evo-
lutionarily and operates in both vertebrates and inverte-
brates. Notch signalling pathways are activated by
interactions between adjacent cells, and influence the
regulation of cell, tissue, and organ differentiation and
development [15]. The Notch signalling pathway in-
cludes receptors, ligands, DNA-binding proteins, and ef-
fector molecules. There are four receptors (Notch1 to
Notch4) and five ligands (DII1, DII3, DII4, Jaggedl, and
Jagged2) in mammalian cells. Notch signalling occurs
close to the cell surface receptor upon Notch ligand
binding, with the receptor releasing a notch receptor
intracellular domain (NICD) from the cell membrane.
This NICD translocates to the nucleus to regulate gene
transcription, thereby influencing cell proliferation and
differentiation [15]. Notch signalling is involved with cell
fate decisions including proliferation, lineage commit-
ment, and terminal differentiation in many types of adult
stem cells [16]. In heart tissue-derived c-kitPOS CSCs, ac-
tivation of Notch1 signalling directly upregulates Nkx2.5
expression, promoting cardiomyocyte commitment [17].
Because Notch signalling has a remarkable cell-context
dependency [18], we investigated whether Notch signal-
ling affects c-KitPOS BMSCs.
In the present study, we assessed whether populations
of BMSCs included c-KitPOS cells that displayed CSC dif-
ferentiation properties and evaluated the effectiveness of
Notch signalling activation for promoting differentiation
of c-KitPOS BMSCs. We identified c-KitPOS/NKX2.5POS
BMSCs in total BMSC populations, and activation of
Notch1 promoted multilineage differentiation of these
cells. These findings suggest that targeted modulation of
Notch1 signalling may be useful in stem cell translational
medicine.
Methods
Isolation, morphology, and functional identification of rat
BMSCs
Sprague–Dawley rats (6 weeks old, both genders) were
purchased from the Experimental Animal Center of
Guangdong Medical University, Zhanjiang, China. All ani-
mal procedures were conducted in accordance with proto-
cols approved by the Institutional Animal Care and Use
Committee of Guangdong Medical University. Unsorted
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to a previously described protocol [19,20]. Briefly, rats
were sacrificed with chloroform anaesthesia, and fe-
murs were aseptically removed and soaked in 75% etha-
nol for 10 minutes. Bone marrow was then flushed out
using Dulbecco’s modified Eagle’s medium (DMEM;
Hyclone, Beijing, China) supplemented with 2% (v/v)
foetal bovine serum (FBS; Gibco, Grand Island, NY,
USA). The released cells were collected, and the red
blood cells in collected bone marrow-derived primary
cells were removed using red blood cell lysis buffer
(Sigma-Aldrich, Shanghai, China). Cell pellets were
washed three times with phosphate-buffered saline (PBS)
and cells were resuspended in DMEM supplemented with
10% FBS, 100 U/ml recombinant rat leukaemia inhibitory
factor (LIF3010; EMD Millipore, Billerica, MA, USA),
100 U/ml penicillin, and 0.1 μg/ml streptomycin, and
were maintained at 37°C in saturated humidity with 5%
carbon dioxide. After 2 days, nonadherent cells were
removed, and medium changes were performed every 3
days thereafter. Cell morphology was monitored under
an inverted microscope. Fourth passage cells were used
for differentiation experiments. Total BMSCs (3 × 103
cells/cm2) were seeded in six-well plates. For osteogen-
esis, cells were treated with inducing medium
(RASMX-90021; Cyagen Biosciences, Guangzhou,
China) for 3 weeks. Cells were then fixed with 4% for-
maldehyde for 30 minutes and stained with Alizarin
Red. For adipocyte differentiation, cells were main-
tained in adipocyte genesis medium (RASMX-90031;
Cyagen Biosciences) for 3 weeks. Cells were then
stained with Oil Red O [21]. For smooth muscle cell
(SMC) differentiation, cells grown on coverslips were
treated with medium containing 10 ng/ml transforming
growth factor-β1 (100–21; PeproTech, Rocky Hill, NJ,
USA) for 8 days and then subjected to immunofluores-
cence staining for the SMC marker smooth muscle
myosin heavy chain.
Isolation, cloning, morphology, and identification of
c-KitPOS/NKX2.5POS BMSCs
Third-passage BMSCs were harvested and c-KitPOS cells
isolated using a magnetic activated cell sorting (MACS)
system (Miltenyi Biotec, Bergisch Gladbach, Germany)
as described previously [22,23]. Diluted c-KitPOS cells
were seeded in six-well plates and maintained in DMEM
supplemented with 10% FBS, 0.2 mmol/l glutathione
(G5763; Sigma Aldrich), 2.5 U/ml erythropoietin (287-
TC-500; R&D Systems, Minneapolis, MN, USA), and 10
ng/ml recombinant fibroblast growth factor (400–29;
PeproTech). Cellular morphology of single cell-derived
clones was monitored at 3, 7, 14, 21, and 28 days, and
confluent cells were used to assess marker expression by
immunofluorescence staining and RT-PCR analysis. Cellsthat were positive for c-Kit and early cardiac marker
NKX2.5, but negative for markers of mature cardiomyocytes
(α-sarcomeric actin, cardiac troponin T (cTnT)), SMCs
(SM22α), and endothelial cells (von Willebrand factor
(vWF)), were used in subsequent experiments. These cells
were classed as c-KitPOS/NKX2.5POS BMSCs. Differentiation
of c-KitPOS/NKX2.5POS BMSCs into osteocytes, adipocytes,
and SMCs was monitored as per the total BMSCs described
above.
NICD overexpression by adenovirus-mediated transduction
NICD cDNA (5,468 to 7,820 nucleotides; NM_001105721)
was obtained from the cDNA library of Genechem (Shang-
hai, China) with the following primers: 5′-AGG TCG ACT
CTA GAG GAT CCC GCC ACC ATG CGC AAG CGC
AGG CGG CA-3′ and 5′-TCC TTG TAG TCC ATA
CCC TTA AAT GCC TCT GGA ATG TGG G-3′. The
2,399 base pair PCR product was cloned into a linearised
adenovirus plasmid GV314 (Genechem) with T4 DNA
ligase and transfected into competent Escherichia coli
cells. Positive clones were selected by ampicillin resistance
and then sequenced by ABI3730 sequencing analysis
(Invitrogen, Shanghai, China). The NICD overexpression
adenovirus (NICD-Ad) was packaged in HEK293T cells
and purified with an Adeno-X™ Virus Purification Kit (BD
Biosciences, San Jose, CA, USA). The endpoint dilution
method was used to determine the viral titre. Adenovirus
particles expressing a scrambled sequence (NC-Ad; pur-
chased from Genechem) served as a negative control.
For cell infection, total BMSCs and c-KitPOS/NKX2.5POS
BMSCs were seeded in six-well plates with or without
coverslips. After 24 hours, the NICD-Ad or NC-Ad virus
was added to the cells at a multiplicity of infection of 100
in the presence of 4 μg/ml polybrene. Cells not transfected
with virus were classified MOCK. Twenty-four hours after
infection, medium was changed to complete DMEM and
then changed every 3 days. After 72 hours, the viral infec-
tion efficiency was assessed under fluorescence micros-
copy. Cells were harvested for experiments at day 8 after
infection.
Determination of Notch receptors and c-Kit expression by
flow cytometry
Total BMSCs and c-KitPOS/NKX2.5POS BMSCs (2 × 106
cells) were fixed in cold 70% ethanol overnight. After
washing with PBS, cells were incubated with primary
antibodies against Notch1 to Notch4 and c-Kit at room
temperature for 1 hour. Following three washes with PBS,
cells were incubated with fluorescein isothiocyanate-
conjugated or phycoerythrin-conjugated IgG in the dark at
room temperature for 30 minutes. Samples were then sub-
jected to flow cytometric analysis using a BD FACSCanto
II (BD Biosciences). Data were analysed with FACSDiva
software (BD Biosciences).
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NKX2.5POS BMSC differentiation
Total BMSCs and c-KitPOS/NKX2.5POS BMSCs were
maintained in complete DMEM and seeded in six-well
plates with coverslips or 6 cm dishes. For induced differ-
entiation, five treatment groups were established and
cultured in DMEM + 10% FBS: Jagged1, with 2.5 μg/ml
Jagged1 Fc Chimera (99-JG; R&D Systems); IgG, with
2.5 μg/ml IgG (14131; Sigma Aldrich); Notch1 inhibitor
N-(2S-(3,5-difluorophenyl)acetyl)-L-alanyl-2-phenyl-1,1-
dimethylethyl ester-glycine (DAPT), with 2.5 μg/ml
Jagged1 Fc Chimera and 10 μmol/ml DAPT (D5942;
Sigma Aldrich) dissolved in dimethyl sulfoxide; DMSO,
with ≤0.03% dimethyl sulfoxide (v/v); and MOCK, with
medium alone. Medium was changed every 3 days. After
8 days, cells grown on coverslips were subjected to im-
munofluorescence staining, while cells grown in dishes
were subjected to mRNA expression analysis.
RNA isolation, reverse transcription, and PCR
Total BMSCs and c-KitPOS/NKX2.5POS BMSCs were
subjected to mRNA expression analysis. Total RNA was
extracted with RNAiso Plus (D9108B; TaKaRa, Dalian,
China). To generate cDNA, total RNA (1 μg) was re-
verse transcribed using an RT kit (DRR047A; TaKaRa)
with an oligo(dT18) primer. Quantitative PCR was con-
ducted using a LightCycler480 II instrument (Roche
China, Guangzhou, China), and semi-quantitative PCR was
performed using a Mastercycler® Gradient Thermal cycler
(Eppendorf, Wesseling-Berzdorf, Germany). Primers were
synthesised by Sangon Biotech (Shanghai, China) and are
listed in Additional file 1. For quantitative PCR, reaction
volumes of 20 μl included 10 μl SYBR® Premix Ex Taq™
(catalogue number DRR820A; Takara), 0.8 μl each primer
(10 μM), 2 μl cDNA, and 6.4 μl ddH2O. PCR amplification
conditions were as follows: denaturation at 95°C for
30 seconds, followed by 45 cycles of 95°C for 5 seconds,
and 60°C for 20 seconds. The relative amount of target
mRNAs was determined using cycle threshold values and
plotted as the fold change compared with control groups
(2−ΔΔCT method). Semi-quantitative PCR conditions were
95°C for 5 minutes, followed by 31 cycles at 95°C for
45 seconds, 58°C for 45 seconds, and 72°C for 1 minute.
PCR products were separated by 1.5% agarose gel electro-
phoresis and visualised under ultraviolet light using a gel
documentation system (Bio-Rad, Hercules, CA, USA). For
all PCR analyses, the expression level of β-actin served as
a loading control.
Immunofluorescence staining
Cells grown on coverslips were subjected to indirect im-
munofluorescence to identify the expression and loca-
tion of cleaved Notch1 (NICD) and differentiation
markers. Following overnight incubation with primaryantibodies at 4°C, cells were washed three times with PBS.
Cells were then incubated with fluorescein isothiocyanate-
conjugated or phycoerythrin-conjugated IgG (H + L;
Proteintech, Wuhan, China) at room temperature for
30 minutes. Nuclei were counterstained with 4′,6-
diamidino-2-phenylindole (5 μg/ml) at room temperature
for 15 minutes. Images were captured under a laser
scanning confocal microscope (TCS SP5 II; Leica, Wetzlar,
Germany). Primary antibodies used are listed in Additional
file 2.
Statistical analysis
Statistical analyses were performed using PRISM Software
(Version 5; GraphPad Software, San Diego, CA, USA).
Data are expressed as the mean ± standard deviation. Stu-
dent’s t test was used to analyse differences between two
groups. For multiple group comparisons, analysis of variance
was carried out followed by the Student–Newman–Keuls
test. P <0.05 was considered statistically significant.
Results
Isolation of c-KitPOS/NKX2.5POS cells from total BMSCs and
assessment of cellular morphology
Total BMSCs are a heterogeneous cell population in-
cluding various phenotypical cell subpopulations [24].
We successfully isolated BMSCs from rat femurs accord-
ing to a protocol described previously [19,20]. Unsorted
total BMSCs displayed a typical fibroblast-like morph-
ology (Figure 1A,B,C). c-Kit is a receptor tyrosine kinase
which is bound by stem cell factor to activate signalling
pathways crucial for stem cell functions such as heart
tissue-derived CSC migration [25]. Furthermore, c-Kit is
a relatively stable stem cell marker [26] which can be re-
liably detected in heart tissue-derived CSCs even after
40 passages [27]. We employed MACS to isolate c-
KitPOS cells from total BMSCs. Single-cell cloning was
then used to establish c-KitPOS and NKX2.5POS cells that
were negative for GATA-4, cTnT, SM22α, and vWF ex-
pression, as determined by immunofluorescence staining
and semi-quantitative RT-PCR (Figure 2A,C). These
cells were defined as c-KitPOS/NKX2.5POS BMSCs, and
single c-KitPOS/NKX2.5POS BMSCs could form clones
well (see Additional file 3). c-KitPOS/NKX2.5POS BMSCs
exhibited a fibroblast-like morphology similar to that of
total BMSCs, and there were no obvious morphological
differences between the two cell types (Figure 1). How-
ever, c-KitPOS/NKX2.5POS BMSCs grew slower than the
total BMSCs, but faster than heart tissue-derived CSCs
(see Additional file 4).
c-Kit and Notch receptor expression by total BMSCs and
c-KitPOS/NKX2.5POS BMSCs
We performed flow cytometry to analyse the expression
of c-Kit and Notch1 to Notch4 receptors on total





Figure 1 Representative morphology of total and c-KitPOS/NKX2.5POS bone marrow mesenchymal stem cells. (A) Bone marrow mesenchymal
stem cells (BMSCs) gradually showed fibroblast-like shapes by day 3 after plating. (B) Cells reached confluency at day 14. (C) High magnification
of confluent BMSCs. (D) A single c-KitPOS/NKX2.5POS BMSC showing a polygonal shape at 3 days after plating. (E) The cell clone at confluency after
21 days. (F) High magnification of confluent c-KitPOS/NKX2.5POS BMSCs. Scale bar: (A, B, D, E) 30 μm, and (C, F) 60 μm. Original magnifications:
(A, B, D, E) ×100, and (C, F) ×200.
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MACS sorting, 7.3% of total BMSCs were c-Kit-
positive, while 84.4% of cells were c-Kit-positive
following a single round of sorting (Figure 2B). This
result indicates that MACS is a suitable method for
enriching c-Kit-positive cell populations from BMSCs.
Varied expression levels of Notch receptors were de-
tected in total BMSCs and c-KitPOS/NKX2.5POS
BMSCs (Figure 2D). Notch1 was the predominantly
expressed form of receptor in both total BMSC and c-
KitPOS/NKX2.5POS BMSC populations, Following sort-
ing, Notch1-positive cells increased from 67.2% in total
BMSCs to 77.8% in c-KitPOS/NKX2.5POS BMSCs
(Figure 2D). These results suggest that Notch1 signal-
ling plays a crucial role in the biology of c-KitPOS/
NKX2.5POS BMSCs, which supports our rationale for
investigating Notch1.Forced Notch1-NICD expression leads to Notch1 signalling
activation and multilineage differentiation in total BMSCs
and c-KitPOS/NKX2.5POS BMSCs
Total BMSCs and c-KitPOS/NKX2.5POS BMSCs were
treated with specific agents to induce osteogenic, adipo-
genic, and SMC differentiation, and differentiated cells
expressed typical markers of differentiation (Figure 3).
Both total BMSCs and c-KitPOS/NKX2.5POS BMSCs
therefore displayed multilineage differentiation potential,
suggesting that these cells could be induced to differenti-
ate into desired cell types by other cues.
Binding of ligand Jagged1 to the Notch1 receptor re-
leases NICD to the nucleus. NICD forms a protein com-
plex with CSL(CBF1/Su(H)/Lag-1), which then turns the
co-repressor into a co-activator, subsequently activating
transcription of target genes [15]. We constructed an
adenovirus to overexpress NICD (NICD-Ad) independent
Figure 2 (See legend on next page.)
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Figure 2 Phenotypic identification of c-KitPOS/NKX2.5POS bone marrow mesenchymal stem cells. (A) Confluent, c-KitPOS/NKX2.5POS bone marrow
mesenchymal stem cells (BMSCs) were passaged and third-passage cells were subjected to immunofluorescence staining for c-Kit, NKX2.5, and
α-sarcomeric actin (α-SA). Unsorted total BMSCs served as control. (B) Assessment of c-Kit expression in total BMSCs before and after magnetic
activated cell sorting by flow cytometric analysis. (C) Semi-quantitative RT-PCR analysis of markers for stem cells (c-Kit), cardiomyocytes (NKX2.5,
GATA-4, and cardiac troponin T (cTnT)), smooth muscle cells ( SM22α) and endothelial cells (von Willebrand factor (vWF)). A sample from a
neonatal Sprague–Dawley rat heart was used as positive control. (D) Flow cytometry was performed to detect the presence of Notch1 to Notch4
receptors. For immunofluorescence staining, target proteins were detected with fluorescein isothiocyanate (FITC)-conjugated or phycoerythrin
(PE)-conjugated IgG. Images were captured by fluorescence microscopy. Scale bar: 50 μm. For semi-quantitative RT-PCR analysis, β-actin mRNA
was used as an internal control. For flow cytometric analysis, isotype control IgG was used to set the threshold.
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Ad, we observed enhanced Hes1 mRNA expression in
both total BMSCs and c-KitPOS/NKX2.5POS BMSCs, com-
pared with expression in controls (NC-Ad and MOCK;
Figure 4). These results suggest that forced expression of
Notch1-NICD in total BMSCs and c-KitPOS/NKX2.5POS
BMSCs led to activation of Notch1 signalling.
We next evaluated the expression of markers of cardio-
myocyte (NKX2.5 and cTnT), SMC (SM22α), and endo-
thelial cell (vWF) differentiation. Protein and mRNA
levels of NKX2.5, cTnT, SM22α, and vWF were upregu-
lated in NICD-overexpressing total BMSCs and c-KitPOS/
NKX2.5POS BMSCs (Figure 5). These data indicate that
forced expression of NICD in total BMSCs and c-KitPOS/Figure 3 Functional identification of total and c-KitPOS/NKX2.5POS bone ma
marrow mesenchymal stem cells (BMSCs) and c-KitPOS/NKX2.5POS BMSCs w
with Alizarin Red and Oil Red O, respectively. (B) For smooth muscle cell d
supplemented medium for 8 days, and then subjected to immunofluoresce
Target proteins were detected with fluorescein isothiocyanate-conjugated
(DAPI). Original magnification: (A) ×200. Scale bar: 30 μm.NKX2.5POS BMSCs activated Notch1 signalling and in-
duced multilineage differentiation, supporting a role for
Notch1 signalling in the differentiation of BMSCs. Inter-
estingly, we also found that forced activation of Notch1 in
c-KitPOS/NKX2.5POS BMSCs led to enhanced osteogenic
and adipogenic differentiation (see Additional file 5). This
probably reflects the complexity of Notch1 signalling in
stem cell differentiation.
Jagged1-triggered Notch1 signalling activation induces
multi-lineage differentiation
We treated total BMSCs and c-KitPOS/NKX2.5POS BMSCs
with Jagged1 to activate Notch1 signalling, as Notch1 was
the predominant Notch receptor expressed by these cells.rrow mesenchymal stem cells. (A) Uninduced and induced bone
ere stained after 21 days of osteogenic or adipogenic differentiation
ifferentiation, BMSCs were treated with transforming growth factor-β1-
nce (IF) staining for smooth muscle myosin heavy chain (SM-MHC).
IgG. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole
Figure 4 Forced NICD expression activation of Notch1 signalling in total and c-KitPOS/NKX2.5POS bone marrow mesenchymal stem cells. Total
bone marrow mesenchymal stem cells (BMSCs) and c-KitPOS/NKX2.5POS BMSCs were infected with NICD-Ad or NC-Ad, with uninfected cells
serving as an additional control (MOCK). After 8 days, the cells were harvested for (A) immunofluorescence staining for notch receptor intracellular
domain (NICD) and Hes1, and (B) real-time quantitative RT-PCR analysis of Hes1 mRNA expression. For immunofluorescence staining, target
proteins were detected with fluorescein isothiocyanate-conjugated IgG. (C) Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI).
Images were captured by confocal microscopy and merged. Scale bar: 50 μm. Triplicate experiments were performed for real-time quantitative
RT-PCR analysis (n = 3). ***P <0.001 versus other groups. NC-Ad, negative control-expressing adenovirus; NICD-Ad, NICD-expressing adenovirus.
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ling in both total BMSCs and c-KitPOS/NKX2.5POS BMSCs
as evidenced by upregulation of Hes1 and NICD, while the
Notch1 inhibitor DAPT attenuated this effect (Figure 6).
Jagged1-induced Notch1 activation in c-KitPOS/NKX2.5POS
BMSCs was stronger than that in total BMSCs, as indi-
cated by increased immunofluorescence signals and Hes1
levels in Jagged1-treated cells (Figure 6).
We next assessed the differentiation of total BMSCs
and c-KitPOS/NKX2.5POS BMSCs exposed to Jagged1.
Jagged1-induced Notch1 signalling led to enhanced
NKX2.5, cTnT, SM22α, and vWF expression, while in-
hibition of Notch1 signalling by DAPT reduced theirexpression at both mRNA and protein levels (Figure 7).
These findings demonstrate that Jagged1-triggered Notch1
signalling induced differentiation of total BMSCs and c-
KitPOS/NKX2.5POS BMSCs into cardiomyocyte, SMC,
and endothelial cell lineages.
Jagged1-activated Notch1 signalling predominantly
induces cardiomyocyte differentiation in c-KitPOS/NKX2.5POS
BMSCs
Following exposure of c-KitPOS/NKX2.5POS BMSCs to
exogenous Jagged1, the increases in expression of car-
diomyocyte and endothelial cell lineage markers were
much stronger than those in total BMSCs (Figure 7A).
Figure 5 Forced NICD expression induces multilineage differentiation of total and c-KitPOS/NKX2.5POS bone marrow mesenchymal stem cells. Total
bone marrow mesenchymal stem cells (BMSCs) and c-KitPOS/NKX2.5POS BMSCs were infected with NICD-Ad or NC-Ad, with uninfected cells serving as
an additional control (MOCK). After 8 days, the cells were harvested for (A) real-time quantitative RT-PCR analysis and (B) immunofluorescence staining
for markers for cardiomyocytes (NKX2.5 and cardiac troponin T (cTnT)), smooth muscle cells (SM22α), and endothelial cells (von Willebrand factor
(vWF)). Triplicate experiments were performed for real-time quantitative RT-PCR analysis (n = 3). *P <0.05, ***P <0.001, #P <0.05, ##P <0.01, ###P <0.001
versus other associated groups. For immunofluorescence staining, images were captured by confocal microscopy. Target proteins were detected with
phycoerythrin-conjugated or fluorescein isothiocyanate-conjugated IgG. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Scale
bar: 50 μm. EC, endothelial cell; NC-Ad, negative control-expressing adenovirus; NICD, notch receptor intracellular domain; NICD-Ad, NICD-expressing
adenovirus; SMC, smooth muscle cell.
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SMC differentiation marker SM22α (Figure 7A). These
findings suggest that c-KitPOS/NKX2.5POS BMSCs are
more responsive to Notch1 signalling stimuli than total
BMSCs. We further evaluated the tendency of Jagged1-treated c-KitPOS/NKX2.5POS BMSCs to differentiate into
cardiomyocytes, SMCs, and endothelial cells by counting
cTnT-positive, SM22α-positive, and vWF-positive cells
in 10 representative fields of view to determine the per-
centages of positive cells in each lineage. Jagged1-
Figure 6 (See legend on next page.)
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Figure 6 Exogenous Jagged1 activation of Notch1 signalling in total and c-KitPOS/NKX2.5POS bone marrow mesenchymal stem cells. Total bone
marrow mesenchymal stem cells (BMSCs) and c-KitPOS/NKX2.5POS BMSCs were classified into Jagged1, IgG, N-(2S-(3,5-difluorophenyl)acetyl)-L-alanyl-2-
phenyl-1,1-dimethylethyl ester-glycine (DAPT), dimethyl sulfoxide (DMSO), and MOCK treatment groups (see Methods). After 8 days, activation of
Notch1 signalling was assessed by immunofluorescence staining of notch receptor intracellular domain (NICD) and Hes1 protein expression
(A) and quantitative RT-PCR analysis of Hes1 mRNA expression (B). For immunofluorescence staining, target proteins were detected with fluorescein
isothiocyanate-conjugated IgG. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Scale bar: 50 μm. Representative images were
captured by confocal microscopy. Triplicate experiments were performed for real-time quantitative RT-PCR analysis (n = 3). ***P <0.001 versus
other groups.
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NKX2.5POS BMSCs facilitated predominately cardiomyo-
cyte differentiation, while differentiation into endothelial
and SMC lineages was much weaker (Figure 8).
Discussion
Stem cell therapy is emerging as a promising treatment
strategy for MI. Current investigations are endeavouring
to identify the most suitable type of stem cell for MI
treatment [28,29]. The feasibility, safety, and effective-
ness of stem cell transplantation based on heart tissue-
derived CSCs have been demonstrated in animal models
of MI. Recent results of several phase I clinical trials
have also have provided encouraging results [11,12].
However, the SWISS-AMI trial has generated conflicting
results [5]. A potential explanation for the inconsistent
results of these clinical trials may be the variability of
cell types used [8]. Ellison and colleagues have
highlighted the necessity of heart tissue-derived CSCs
for MI repair [10]. However, considering the potential
for damage caused by the acquisition of heart tissue for
CSCs, there is a need for an alternative cell source to
substitute for heart tissue-derived CSCs.
Compared with heart tissue-derived CSCs, BMSCs are
able to be handled and expanded more easily [14]. Fur-
thermore, their phenotype is not influenced by con-
fluency during culture expansion [30]. Additionally, a
meta-analysis concluded that BMSCs have promising
prospects for MI treatment [31]. BMSCs exhibit a multi-
lineage in vitro differentiation potential, including cardi-
omyocytes. However, the functions of BMSCs in vivo are
mainly mediated in a paracrine manner [32] and these
cells do not directly differentiate into functional cardio-
myocytes [33]. A possible reason for this indirect effect
may be the multiple subpopulations of cells with different
differentiation potentials that constitute total BMSCs.
Screening purified BMSCs for highly-efficient differenti-
ation to cardiomyocytes could therefore be of great benefit
to stem cell-based cardiac repair.
Because Notch signalling plays a critical role in stem
cell differentiation into cardiomyocytes [17,34,35], we
examined whether forced activation of Notch1 signalling
could efficiently induce cardiac differentiation of BMSCs.
Therefore, we infected unsorted total BMSCs with arecombinant NICD-expressing adenovirus. Forced ex-
pression of NICD in BMSCs promoted multilineage dif-
ferentiation, including to cardiomyocytes, suggesting
that activation of the Notch1 signalling pathway is
functionally relevant in BMSC differentiation.
We next examined the function of Notch1 signalling
on the c-KitPOS/NKX2.5POS subtype of BMSCs. We suc-
cessfully isolated c-KitPOS cells from total BMSCs using
MACS as described previously [22,23,25]. Cell clones
positive for NKX2.5 were then successfully derived from
single c-KitPOS cells. Finally, c-KitPOS/NKX2.5POS cells
were found to be negative for markers of adult cardio-
myocyte (α-sarcomeric actin, cTnT), SMC (SM22α), and
endothelial cell (vWF) differentiation. The purity of c-
KitPOS/NKX2.5POS BMSCs after a single MACS reached
84.4%, significantly higher than that of the 7.3% in total
BMSCs before sorting.
The use of c-KitPOS BMSCs in MI treatment has been
proposed by previous reports [36,37]; however, we fur-
ther investigated the c-KitPOS/NKX2.5POS subpopulation
and showed that, of the four known Notch receptors,
these cells predominantly expressed Notch1. This obser-
vation led us to examine the effects of ligand-induced
activation of Notch1 signalling on differentiation of c-
KitPOS/NKX2.5POS BMSCs. c-KitPOS/NKX2.5POS BMSCs
proliferated slower than total BMSCs, but faster than c-
KitPOS CSCs derived from rat hearts, indicating that c-
KitPOS/NKX2.5POS BMSCs can be expanded more easily
than heart tissue-derived c-KitPOS CSCs.
Notch signalling contributes to stem cell quiescence,
proliferation, and differentiation depending on the
context in which the signal is activated [38]. Boni and
colleagues reported that Notchl directly regulates
NKX2.5 promoter activity in mouse heart-derived
CSCs, thereby positively regulating cardiomyocyte dif-
ferentiation [17]. Chen and colleagues demonstrated
that activation of Notch signalling in mouse cardio-
sphere cells – a heterogeneous progenitor cell population –
promotes SMC differentiation through a J kappa-
recombining binding protein-dependent signalling
pathway in vitro [39]. However, activation of Notch sig-
nalling in embryonic stem cells has been reported to
produce opposite results [40]. A recent study by Matsuda
and colleagues proposed that the cell density of heart
c-KitPOS/NKX2.5POS BMSCTotal BMSCA
B
Figure 7 (See legend on next page.)
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Figure 7 Jagged1 activation of Notch1 signalling induces multilineage differentiation of total and c-KitPOS/NKX2.5POS bone marrow mesenchymal stem
cells. Total bone marrow mesenchymal stem cells (BMSCs) and c-KitPOS/NKX2.5POS BMSCs were classified into Jagged1, IgG, N-(2S-(3,5-difluorophenyl)acetyl)-
L-alanyl-2-phenyl-1,1-dimethylethyl ester-glycine (DAPT), dimethyl sulfoxide (DMSO), and MOCK treatment groups (see Methods). After 8 days,
the expression of differentiation markers for cardiomyocytes (NKX2.5 and cardiac troponin T (cTnT)), smooth muscle cells (SM22α), and endothelial cells
(von Willebrand factor (vWF)) were examined by (A) real-time quantitative RT-PCR and (B) immunofluorescence staining. Triplicate experiments were
performed for real-time quantitative RT-PCR analysis (n = 3). *P <0.05, **P <0.01, ##P <0.01, ###P <0.001 versus other associated groups. For
immunofluorescence staining, target proteins were detected with phycoerythrin-conjugated or fluorescein isothiocyanate-conjugated IgG.
Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Representative images were captured by confocal microscopy. Scale
bar: 50 μm.
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status and differentiation potential, influencing in vivo
CSC function and potential utility for MI therapy [41].
These inconsistencies highlight the need for further efforts
to clarify the exact role of Notch1 signalling in c-KitPOS/
NKX2.5POS BMSC differentiation.
We found that Notch1 was the predominant Notch re-
ceptor form expressed by both total BMSCs and c-
KitPOS/NKX2.5POS BMSCs. We therefore treated these
two types of cells with exogenous Jagged1 to mimic the
binding of ligand and receptor. As shown in our pilot in-
vestigation, 2.5 μg/ml exogenous Jagged1 maximised
Hes1 mRNA expression (see Additional file 6); we there-
fore treated the cells with 2.5 μg/ml Jagged1 in the subse-
quent experiments. Jagged1 activated Notch1 signalling
and promoted differentiation of both total BMSCs and c-
KitPOS/NKX2.5POS BMSCs into cardiomyocyte, SMC, andFigure 8 Activation of Notch1 signalling favours cardiac differentiation
of c-KitPOS/NKX2.5POS bone marrow mesenchymal stem cells. Positive
immunofluorescence (IF) staining was assessed for cardiac troponin T
(cTnT), smooth muscle cells (SM22α), and von Willebrand factor (vWF)
in 10 representative fields of Jagged1-treated c-KitPOS/NKX2.5POS
bone marrow mesenchymal stem cells. Ratios to 4′,6-diamidino-2-
phenylindole-positive cells represent differentiation potentials for
cardiomyocytes, smooth muscle cells, and endothelial cells.endothelial cell lineages. Furthermore, expression levels of
cardiomyocyte and endothelial cell lineage markers in cells
derived from c-KitPOS/NKX2.5POS BMSCs were greater
than those of cells derived from total BMSCs. Moreover,
differentiation of the cardiomyocyte lineage was favoured
over differentiation of endothelial cell and SMC lineages
in c-KitPOS/NKX2.5POS BMSCs. This suggests that c-
KitPOS/NKX2.5POS BMSCs preferentially differentiate into
cardiac myocytes following activation of Notch1 signal-
ling. These in vitro results support a previous report
which found that Notch1 signalling in BM-derived cells is
critical for cardiac repair [42]. Activation of Notch1 signal-
ling therefore promotes c-KitPOS/NKX2.5POS BMSC dif-
ferentiation, suggesting that targeting Notch1 signalling
may be beneficial for stem cell translational medicine in
MI repair.
At least two phase I clinical trials have demonstrated
that transplantation of homogeneous heart-derived CSCs
to patients is beneficial for heart function recovery [5-7].
However, the isolation of CSCs from heart tissue is po-
tentially damaging and in vitro maintenance of cell pop-
ulations is complex and time consuming. An improved
understanding of the origin of CSCs should aid progress
towards effective, viable treatment options. Presently, lit-
tle is known concerning the origin of heart-derived
CSCs. Heart resident CSCs may be either cells that have
resided there from foetal life onwards or could come
from the bone marrow or circulation [43]. An early report
demonstrated that sex-mismatched heart transplantation
patients possessed recipient-derived Y chromosomes in
the nuclei of some cardiomyocytes, suggesting that bone
marrow or circulation-derived stem cells had participated
in the regenerative process [44]. We aimed to identify
these alternative cells from bone marrow that possess
properties of heart-derived CSCs.
We found that c-KitPOS/NKX2.5POS cells within total
BMSC populations display some properties of CSCs, be-
ing positive for NKX2.5 but negative for markers of
adult cardiomyocytes, SMCs, and endothelial cells. Guo
and colleagues proposed the existence of bone marrow-
derived CSCs that express c-Kit and NKX2.5 [45]. Fur-
thermore, these bone marrow-derived CSCs could repair
injured hearts following transplantation to MI-model an-
imals. Whether our current c-KitPOS/NKX2.5POS BMSCs
Ding et al. Stem Cell Research & Therapy  (2015) 6:91 Page 14 of 15represent the same cell population as those identified by
Guo and colleagues is interesting and warrants further
study.
Notch1 signalling plays a pivotal role in the fate of heart-
derived CSCs [17]. We found that c-KitPOS/NKX2.5POS
BMSCs were predisposed to Notch1 signalling-induced
multilineage differentiation, with a preference for cardiac
differentiation when compared with total BMSCs. Fur-
ther clarification of the differences between c-KitPOS/
NKX2.5POS BMSCs and c-KitPOS heart-derived CSCs
may facilitate the clinical use of BMSCs.
Some limitations were present in our investigation.
We provide in vitro evidence concerning Notch1 sig-
nalling in the differentiation of c-KitPOS/NKX2.5POS
BMSCs. However, the effects of Notch1 signalling acti-
vation in c-KitPOS/NKX2.5POS BMSCs in an in vivo set-
ting mimicking transplantation for repair of injured
heart tissue post MI should be assessed in future stud-
ies. Additionally, more differentiation markers could be
examined to better identify cell differentiation commit-
ment and changes to cellular electrophysiological func-
tions. Future studies should also focus on the optimal
timing and degree of Notch signalling activation to pro-
mote cardiomyocyte differentiation of c-KitPOS/NKX2.5POS
BMSCs. The role of crosstalk between Notch and other
signalling pathways should also be considered.
Conclusions
Our study demonstrates the existence of c-KitPOS/
NKX2.5POS cells within total BMSC populations. These
cells exhibit unique properties in colonic, proliferative,
and multilineage differentiation potentials. c-KitPOS/
NKX2.5POS BMSCs are predisposed to Notch1-induced
cell differentiation when compared with total BMSCs.
Targeted activation of Notch1 signalling in c-KitPOS/
NKX2.5POS BMSCs leads to multilineage differentiation,
suggesting that Notch1 signalling is a potential target for
stem cell translational medicine research.
Additional files
Additional file 1: is Table S1 presenting the primers used for PCR.
bp, base pairs.
Additional file 2: is Table S2 presenting the primary antibodies.
Additional file 3: is Figure S1 showing representative images of
clones derived from cell of c-KitPOS/NKX2.5POS BMSCs. c-KitPOS/
NKX2.5POS BMSCs were diluted into single-cell suspension and plated in
six-well plates allowing it to form clones. Left panel, a small clone (the
number of cells is <50), magnification: ×200; Right panel, two adjacent
larger clones (the number of cells is >50), magnification: ×100.
Additional file 4: is Figure S2 showing the growth curve of total
BMSCs, c-KitPOS/NKX2.5POS BMSC and cardiac c-KitPOS CSC. Total
BMSCs, c-KitPOS/NKX2.5POS BMSCs and cardiac c-KitPOS CSCs were plated
in six-well plates allowing cells to proliferate, and then total cell numbers
were counted every day for consecutive 7 days. For isolation of cardiac
CSCs, hearts form neonatal rat were used, and c-KitPOS cells sorted fromcollagenase and trypsin-treated neonatal rat heart tissues by MACS were
deemed c-KitPOS CSCs. ***P <0.001 versus other groups. Each cell line was
repeated in three wells on every time point (n = 3).
Additional file 5: is Figure S3 showing the adipogenic and
osteogenic differentiation in total BMSCs and c-KitPOS/NKX2.5POS
BMSCs. (A) Total BMSCs and c-KitPOS/NKX2.5POS BMSCs were induced to
adipogenic and osteogenic differentiation using special inducing media
for 3 weeks, and then cells were subjected to quantitative RT-PCR analysis
of markers for adipocyte lineage (PPARγ2, FABP2) and osteoblast lineage
(ALP, osteopontin). Data depicted as mean ± standard deviation from
three independent experiments.(B) c-KitPOS/NKX2.5POS BMSCs were infected
with NICD-Ad and NC-Ad at multiplicity of infection = 100; cells without
adenovirus infection was set as MOCK controls. Eight days post adenovirus
infection, samples were used to quantitative RT-PCR analysis of marker for
osteogenic differentiation (ALP) and adipogenic differentiation (PPARγ2)
expression. Data depicted as mean ± standard deviation from three
independent experiments. **P <0.01 versus other groups; ### P <0.001
versus other groups.
Additional file 6: is Figure S4 showing the effects of Jagged1 on
Hes1 expression. c-KitPOS/NKX2.5POS BMSCs were seeded onto six-well
plates. After cell recovery for a whole night, completed media containing
recombinant Jagged1 (final concentration, 0, 1.25, 2.5 and 5.0 μg/ml) was
added. After 8 days post Jagged1 treatment, samples were used to
quantitative RT-PCR analysis Hes1 (target for judgement of Notch1
activation) expression. Data depicted as mean ± standard deviation from
three independent experiments. ***P <0.001 versus other groups.
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